Home ProductsBoldenone Steroid

Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4

Certification
Good quality Boldenone Steroid for sales
Good quality Boldenone Steroid for sales
Thanks for your professionalism with works ,your quality is very well for us!

—— Lionk-South Africa

Wow,you sent goods so Quickly!I am glad to work with you!

—— Jack-USA

Products are received well. I hope business will boom soon,Lots of order will come youre way.

—— Richard-Holland

test E 250. very little pip. less than a previous source. love the cialis

—— Peter-USA

Just wanted to tell you that the product so far have been amazing. All seem to be very good quality and where easy to cook. Very pleased with it and.

—— Han-Holland

I'm Online Chat Now

Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4

China Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4 supplier
Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4 supplier Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4 supplier Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4 supplier

Large Image :  Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4

Product Details:

Place of Origin: China
Brand Name: Yuancheng
Certification: ISO9001,GMP
Model Number: 55203-24-2

Payment & Shipping Terms:

Minimum Order Quantity: 10-20g
Price: Negotiable
Packaging Details: Discreet and exquisite packing methods to guarantee 100% custom pass rate
Delivery Time: within 3-7 workdays after payment
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: sufficient stock
Contact Now
Detailed Product Description
Name: Dexamethasone Sodium Phosphate Alias: Dexamethasone
CAS: 55203-24-2 Usage: Anti-Inflammatory
Production Capacity: Adequate Stock Export Markets: Global
Certification: USP28/BP2003,GMP, ISO 9001

High Quality Dexamethasone Sodium Phosphate CAS No.: 55203-24-2

Dexamethasone Sodium Phosphate Description

Dexamethasone Sodium Phosphate
1) CAS No:55203-24-2
2) MF:C22H28FNa2O8P
3) MW: 516.41
4) Purity:99%
5) Package:1kg/aluminum cans
6) Appearance:White to kind of white crystal powder.
7) USES: This product is an adrenal cortical hormone tidy medicine. The anti-inflammatory, allergy and suppress the immune DuoZhong pharmacological effects, such as its main mechanism for:
(1) anti-inflammatory effects: corticosteroids ease and prevent the organization to the reaction of the inflammation, thus reduce inflammation performance.
(2) allergy, immunosuppression role: to prevent or inhibiting cell intermediary immune response, delayed allergic reaction, and reduce primary immune response to expand.

 


Item


Dexamethasone Sodium Phosphate


CAS No.
 

55203-24-2



Description


White or almost white crystalline powder


Usage


Anti-inflammatory, anti-allergic API

Specifications


Origin


Shaanxi, China


Standards


EP; BP; USP; CP


Assay


97.0~102.0%

Color of Solution


≤Y2


Water


≤15.0%

Specific rotation


+72°~+80°


PH


7.5~10.5

Dexamethasone Sodium Phosphate, a synthetic adrenocortical steroid, is a white or slightly yellow crystalline powder. It is freely soluble in water and is exceedingly hygroscopic. The molecular weight is 516.41. It is designated chemically as 9-fluoro-11β,17-dihydroxy-16α-methyl-21-(phosphonooxy)pregna-1,4-diene-3, 20-dione disodium salt.

The molecular formula is: C22H28FNa2O8P and the structural formula is:

 

Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4

Glucocorticoid BP2003 99% Dexamethasone Sodium Phosphate CAS 2392-39-4

Dexamethasone Sodium Phosphate Injection is a sterile solution of Dexamethasone Sodium Phosphate for intravenous and intramuscular use. The 4 mg/mL strength may also be used for intra-articular, intralesional and soft tissue administration.

Each mL of Dexamethasone Sodium Phosphate Injection 4 mg/mL contains Dexamethasone Sodium Phosphate, equivalent to 4 mg dexamethasone phosphate or 3.33 mg dexamethasone. Inactive ingredients per mL: 1 mg sodium sulfite anhydrous, 19.4 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection.

Each mL of Dexamethasone Sodium Phosphate Injection 10 mg/mL contains Dexamethasone Sodium Phosphate, equivalent to 10 mg dexamethasone phosphate or 8.33 mg dexamethasone. Inactive ingredients per mL: 1.5 mg sodium sulfite anhydrous, 16.5 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection.

The pH of both concentrations is 7.0-8.5; sodium hydroxide and/or citric acid used, if needed, for pH adjustment. Sealed under nitrogen.

 

Indications and Usage for Dexamethasone Sodium Phosphate

A. By Intravenous or Intramuscular Injection When Oral Therapy is not Feasible:

1. ENDOCRINE DISORDERS

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)

Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)

Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful

Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected

Congenital adrenal hyperplasia

Nonsuppurative thyroiditis

Hypercalcemia associated with cancer

2. RHEUMATIC DISORDERS

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Post-traumatic osteoarthritis

Synovitis of osteoarthritis

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Acute and subacute bursitis

Epicondylitis

Acute nonspecific tenosynovitis

Acute gouty arthritis

Psoriatic arthritis

Ankylosing spondylitis

3. COLLAGEN DISEASES

During an exacerbation or as maintenance therapy in selected cases of:

Systemic lupus erythematosus

Acute rheumatic carditis

4. DERMATOLOGIC DISEASES

Pemphigus

Severe erythema multiforme (Stevens-Johnson syndrome)

Exfoliative dermatitis

Bullous dermatitis herpetiformis

Severe seborrheic dermatitis

Severe psoriasis

Mycosis fungoides

5. ALLERGIC STATES

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:

Bronchial asthma

Contact dermatitis

Atopic dermatitis

Serum sickness

Seasonal or perennial allergic rhinitis

Drug hypersensitivity reactions

Urticarial transfusion reactions

Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)

6. OPHTHALMIC DISEASES

Severe acute and chronic allergic and inflammatory processes involving the eye, such as:

Herpes zoster ophthalmicus

Iritis, iridocyclitis

Chorioretinitis

Diffuse posterior uveitis and choroiditis

Optic neuritis

Sympathetic ophthalmia

Anterior segment inflammation

Allergic conjunctivitis

Keratitis

Allergic corneal marginal ulcers

7. GASTROINTESTINAL DISEASES

To tide the patient over a critical period of the disease in:

Ulcerative colitis (Systemic therapy)

Regional enteritis (Systemic therapy)

8. RESPIRATORY DISEASES

Symptomatic sarcoidosis

Berylliosis

Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

Loeffler's syndrome not manageable by other means

Aspiration pneumonitis

9. HEMATOLOGIC DISORDERS

Acquired (autoimmune) hemolytic anemia

Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)

Secondary thrombocytopenia in adults

Erythroblastopenia (RBC anemia)

Congenital (erythroid) hypoplastic anemia

10. NEOPLASTIC DISEASES

For palliative management of:

Leukemias and lymphomas in adults

Acute leukemia of childhood

11. EDEMATOUS STATES

To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus

12. MISCELLANEOUS

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy

Trichinosis with neurologic or myocardial involvement

13. DIAGNOSTIC TESTING OF ADRENOCORTICAL HYPERFUNCTION

14. CEREBRAL EDEMA associated with primary or metastatic brain tumor, craniotomy or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.

Contact Details
Wuhan Yuancheng Technology Development Co., Ltd.

Contact Person: Ron

Send your inquiry directly to us (0 / 3000)